Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)
- PMID: 30266305
- DOI: 10.1016/j.dld.2018.08.022
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN)
Abstract
Hepatitis C virus (HCV) infection is now considered a systemic disease due to the occurrence of extra-hepatic manifestations. Among these, the renal involvement is frequent. HCV infection, in fact, is strongly associated with proteinuria and chronic kidney disease (CKD) and negatively affects the prognosis of renal patients. In the last few years, availability of more specific and effective drugs against HCV has dramatically changed the clinical course of this disease. These drugs may provide further advantages in the CKD population as a whole by reducing progression of renal disease, mortality rate and by increasing the survival of graft in renal transplant recipients. The strict pathogenetic and prognostic link between HCV infection and CKD requires an ongoing relationship among the healthcare professionals involved in the treatment of both HCV infection and CKD. Therefore, Scientific Societies involved in the care of this high-risk population in Italy have organized a joint expert panel. The aim of the panel is to produce a position statement that can be used in daily clinical practice for the management of HCV infected patients across the whole spectrum of renal disease, from the conservative phase to renal replacement treatments (dialysis and transplantation). Sharing specific evidence-based expertise of different professional healthcare is the first step to obtain a common ground of knowledge on which to instate a model for multidisciplinary management of this high-risk population. Statements cover seven areas including epidemiology of CKD, HCV-induced glomerular damage, HCV-related renal risk, staging of liver disease in patients with CKD, prevention of transmission of HCV in hemodialysis units, treatment of HCV infection and management of HCV in kidney transplantation.
Keywords: Chronic kidney disease; Direct-acting antiviral agents; HCV in renal transplantation; HCV infection.
Copyright © 2018 Roberto Minutolo, Alessio Aghemo, Antonio Chirianni, Fabrizio Fabrizi, Loreto Gesualdo, Edoardo G. Giannini, Paolo Maggi, Vincenzo Montinaro, Ernesto Paoletti, Marcello Persico, Francesco Perticone, Salvatore Petta, Massimo Puoti, Giovanni Raimondo, Maria Rendina, Anna Linda Zignego, on behalf of the Italian Society of Nephrology (SIN), the Italian Association for the Study of the Liver (AISF), the Italian Society of Infectious and Tropical Disease (SIMIT), the Italian Society of Internal Medicine (SIMI). Published by Elsevier Ltd.. All rights reserved.
Similar articles
-
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).Intern Emerg Med. 2018 Dec;13(8):1139-1166. doi: 10.1007/s11739-018-1940-9. Epub 2018 Sep 25. Intern Emerg Med. 2018. PMID: 30255464
-
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).Infection. 2019 Feb;47(1):141-168. doi: 10.1007/s15010-018-1209-2. Epub 2018 Sep 25. Infection. 2019. PMID: 30255389
-
Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN).J Nephrol. 2018 Oct;31(5):685-712. doi: 10.1007/s40620-018-0523-1. Epub 2018 Sep 25. J Nephrol. 2018. PMID: 30255440
-
Summary of the 2018 Kidney Disease Improving Global Outcomes (KDIGO) Guideline on hepatitis C in chronic kidney disease.Semin Dial. 2019 Mar;32(2):187-195. doi: 10.1111/sdi.12768. Epub 2018 Nov 29. Semin Dial. 2019. PMID: 30496617 Review.
-
Management of hepatitis C in patients with chronic kidney disease.World J Gastroenterol. 2015 Jan 14;21(2):408-22. doi: 10.3748/wjg.v21.i2.408. World J Gastroenterol. 2015. PMID: 25593456 Free PMC article. Review.
Cited by
-
Absence of Viral Replication Is Associated With Improved Outcome in Anti-HCV-Positive Patients With Hepatocellular Carcinoma.Liver Int. 2025 Feb;45(2):e16185. doi: 10.1111/liv.16185. Liver Int. 2025. PMID: 39776202 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical